Navigation Links
Schering-Plough Announces Results of the Early ACS Trial
Date:3/30/2009

p>

No statistical difference was observed between the groups in either the primary or secondary endpoints. The primary endpoint occurred in 9.3 percent of the study group (receiving double-bolus plus infusion early administration of eptifibatide 12 or more hours prior to angiography), compared with 10.0 percent of the delayed provisional group (p=0.23). At 30 days, the death or (re)MI rate for the study group was 11.2 percent compared to 12.3 percent for the delayed provisional group (p=0.079).

Significantly higher rates of bleeding were observed in the study group, with 118 patients experiencing a TIMI major bleeding event, compared to 83 in the delayed provisional group (p=0.015). Investigators reported a 7.6 percent vs. 5.1 percent rate of moderate or severe bleeding (p<0.001) in the study group as compared to the delayed provisional group, as measured by the GUSTO scale. Red blood cell transfusions occurred in 8.6 percent of patients in the study group vs. 6.7 percent of patients in the delayed provisional group (p=0.001). There were no significant differences in mortality or any serious adverse events between the two groups.

"This was a very well-treated population that demonstrates the influence of aggressive and sophisticated therapies," said Dr. Newby. "Further evaluation of the safety and efficacy data at one year should provide additional insights into the early use of eptifibatide in this patient population."

Within the trial, the single largest group was PCI patients (n=5,559). An analysis of those randomized to receive early eptifibatide showed that these patients experienced fewer primary and secondary composite events after PCI than those randomized to the delayed provisional eptifibatide strategy.

"Consistent with findings from prior trials, in this double-bolus study, NSTE ACS patients undergoing PCI experienced fewer post-PCI ischemic complications with early eptifibat
'/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
2. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
3. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
4. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
5. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
6. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") announcement ... Directors ("Depomed Board") set a record date to determine ... The Depomed Board will review the request ... received today and contains the information required under Depomed,s ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 /PRNewswire/ ... report published by Persistence Market Research "Global Market ... to Witness Highest Growth by 2022", ... at US$15 Bn by the end of 2015 and ... 6.8% from 2015 to 2022, to account for ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 ... development agreements between biotech companies, military surgical ... solutions & therapies with regards to severe ... positive clinical enhancements for regenerative medicine and ... recent developments, partnerships and advancements in focus ...
Breaking Medicine Technology:Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... JOSEPH, Mich., June 17 GeneGo, Inc., a ... biology, announced,today that they were awarded a Phase ... development of a platform for functional data analysis ... Cancer,Institute, Boston on the project. The system, MetaMiner ...
... 17 ,Oridion Systems Ltd. - (SWX: ORIDN) ... the clinical benefit of end-tidal,CO2 (EtCO2) monitoring ... medical congresses in the United States and ... in San Diego, California, Dr.,Vargo, of the ...
Cached Medicine Technology:GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer 2Oridion Announces Major Medical Research and Congress Presentations 2Oridion Announces Major Medical Research and Congress Presentations 3
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey ... number of Hispanics believe people can positively affect their diabetes, few look beyond ... said making diet changes was important. Far fewer participants mentioned the need for ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today ... management solution, as well as announced the date of its next major release. ... of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. ... water aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... Spring, MD (PRWEB) , ... August 03, 2015 , ... ... the addition of a new associate podiatrist, creating the largest medical practice in the ... foot and ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. Hetal ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4
... BOSTON Ask anyone who suffers from migraine headaches what ... to hear "go into a dark room." And although ... reason why has been unclear. Now scientists at ... visual pathway that underlies sensitivity to light during migraine in ...
... information pathways converge in brain , SUNDAY, Jan. 10 ... exacerbates the already debilitating pain of migraines, even in ... 10 in Nature Neuroscience reveals how visual ... this phenomenon. , Although the findings are unlikely to ...
... ... treatment, Francisco Peinado got plundered by credit card debt and endless collection calls. However, a ... a casualty of medical bankruptcy, which based on a New York Times article, is growing. ... (PRWEB) January 10, ...
... ... Kadrich’s Leading Security Book Endpoint Security, , ... San Jose, CA (PRWEB) January 10, 2010 -- The Security ... announced its support for recently appointed White House cyber-security “czar” Howard Schmidt. A ...
... Mark5inc ... requires to know about attaining whiter and brighter teeth. , ... (PRWEB) January 2, 2010 -- We all were born ... boast our first set of teeth to the world, which were temporary. As we grew, ...
... interpersonal relationships stems weight gain, study finds ... psychotherapy program may work better than traditional health ... obesity from becoming excessively fatter, researchers report. ... by targeting the underlying social and interpersonal difficulties ...
Cached Medicine News:Health News:Study explains why light worsens migraine headaches 2Health News:Study explains why light worsens migraine headaches 3Health News:Why Light Hurts During Migraines 2Health News:Why Light Hurts During Migraines 3Health News:Cancer Patient's Medical Debt Ends in Brother's Credit Card Debt Settlement Victory Over Bankruptcy 2Health News:Cancer Patient's Medical Debt Ends in Brother's Credit Card Debt Settlement Victory Over Bankruptcy 3Health News:Cancer Patient's Medical Debt Ends in Brother's Credit Card Debt Settlement Victory Over Bankruptcy 4Health News:Cancer Patient's Medical Debt Ends in Brother's Credit Card Debt Settlement Victory Over Bankruptcy 5Health News:The Security Consortium Announces Support for White House Cyber Chief Schmidt 2Health News:The Security Consortium Announces Support for White House Cyber Chief Schmidt 3Health News:The Security Consortium Announces Support for White House Cyber Chief Schmidt 4Health News:Mark5inc Teeth Whitening Resource Is Presented To Web 2
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
... Measuring System delivers precise and accurate Measurements! ... receiving a better examination when they see ... equipment. ,User Friendly - after only 5 ... can become very proficient in the operation ...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Curved Cannula for probing and irrigating lacrimal duct. 0.80mm (21 G)...
Medicine Products: